share_log

HC Wainwright & Co. Maintains Buy on ADMA Biologics, Raises Price Target to $6

Benzinga ·  Jan 9 07:09

HC Wainwright & Co. analyst Raghuram Selvaraju maintains ADMA Biologics (NASDAQ:ADMA) with a Buy and raises the price target from $5 to $6.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment